Business Wire

Neuromod Successfully Closes €10.5 Million Series B Financing for Tinnitus Treatment Device Lenire®

Share

Neuromod Devices Limited (“Neuromod”), the Irish medical device company specialising in the treatment of tinnitus, a chronic condition that affects 10-15% of the global population and commonly described as ‘ringing in the ears’, announces it has raised €10.5 million in an oversubscribed Series B financing. The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.

Proceeds from the financing will be used to expand European commercialisation of the Company’s Lenire® tinnitus treatment device; to scale-up manufacturing, progress the Company’s U.S. FDA strategy, and pursue opportunities with the United States Department of Veteran Affairs. It is estimated that roughly 20 million Americans struggle with burdensome chronic tinnitus, while over 2 million U.S. Veterans receive disability payments for service-connected tinnitus, according to the 2019 USVA Annual Benefits Report.

Neuromod’s European expansion began in April 2020 with the opening of the Company’s German office in Bavaria, Germany. Neuromod plans to invest significantly in sales and marketing and will recruit 40 employees over the next 12 months, with roles based initially in Ireland and Germany.

Clinical Trial Results

The Series B financing follows the publication of results of the Company’s first major clinical trial as the cover story in Science Translational Medicine magazine. The trial, which was conducted over 12 weeks, with 326 patients, delivered dramatic improvements in patients’ tinnitus symptoms. More than 80% of those who complied with the prescribed regimen saw an average improvement of about 14 points on a tinnitus severity score of 1 to 100. When the team followed up 12 months post treatment, 80% of the participants had sustained the improvements. The study represents the largest and longest followed-up clinical trial ever conducted in the tinnitus field, and 78% of trial participants said they would recommend the Lenire® treatment to others with tinnitus1.

Lenire® Tinnitus Treatment

Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment shown to soothe and relieve tinnitus. Lenire® has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe.

Dr Ross O’Neill, Founding CEO of Neuromod commented: “We are delighted to announce the successful completion of Series B financing, which will ramp up manufacturing of our Lenire® tinnitus treatment device to meet demand across Europe. The financing will also help us progress market entry into the United States, where there is a significant unmet need, particularly among U.S. veterans for whom tinnitus is the largest and fastest growing cause of service-connected disability. It is fantastic to have the continued support of our lead investors, Fountain Healthcare Partners, as well as Moffett Investments, Medical Device Resources, Kreos Capital and Silicon Valley Bank.”

Dr. Manus Rogan, Chairman of Neuromod and Managing Partner of Fountain Healthcare Partners commented: We are proud to continue to support Neuromod’s mission to improve the quality of life of millions of patients around the world who suffer from tinnitus. This is an exciting time for the Company, and we are confident that it has an effective and safe technology, as proven by the recently published clinical trial results in the prestigious journal Science Translational Medicine. Neuromod has a very bright future and we are excited to play our part in making that happen.”

Cian O’Driscoll from Kreos Capital commented: “We are delighted to be able to support Neuromod further with an additional investment which will help bring Lenire® to more patients suffering from tinnitus. Treatment options for tinnitus patients in the past have been limited and we strongly believe that Lenire® has enormous potential to improve patient outcomes. We are also excited about the prospect of U.S. market entry where there is a substantial need to find new and innovative ways to treat patients whose lives are severely impacted by tinnitus.”

ENDS

About Neuromod Devices Limited

Neuromod Devices Limited (“Neuromod”), headquartered in the Digital Hub, Dublin, Ireland, is a medical technology company, specialising in the design and development of neuromodulation technologies to address the clinical needs of the underserved tinnitus patient population who live with a chronic and debilitating condition. The company was founded in 2010, by Dr. Ross O’Neill and since 2015 has been supported by leading life science venture capital firm Fountain Healthcare Partners. Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in tinnitus for which no standard of care has yet been established. Neuromod’s treatment device Lenire® has been commercialised in Europe and is available in Ireland, Belgium and Germany. Further details on Lenire® including a list of providers can be found on www.lenire.com

Tinnitus affects between 10 and 15% of the global population, and the lives of at least 1 in every 100 people worldwide are severely compromised because of the incessant nature of the illusory sound that is often described as a ringing or buzzing in the ears.

www.NeuromodDevices.com

You can access the full clinical trial results here: https://www.neuromoddevices.com/tenta1results


1 Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study - Science Translational Medicine 07 Oct 2020: Vol. 12, Issue 564, eabb2830 DOI: 10.1126/scitranslmed.abb2830

Contact information

FTI Consulting | Media Relations
Melanie Farrell
Aline Oliveira
T: +353 1 6633686
neuromod@fticonsulting.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala1.12.2020 17:00:00 EETPress release

PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today announced the closing of the previously announced acquisition that gives Kohlberg & Company, LLC (“Kohlberg”) a majority stake in the company. Mubadala Investment Company and Partners Group (acting on behalf of its clients) will have minority shares in the Company. This milestone is a key step for PCI, as Kohlberg and Mubadala will be partnering with PCI’s management team, led by CEO Salim Haffar, to continue the Company’s transformation journey. The team will be adding specific capabilities and geographies organically and inorganically to improve PCI’s client experience and enable its clients to bring life-changing biopharmaceutical therapies to market. Leveraging the global growth trends in biologics and specialized drug therapies, future capabilities include sterile fill finish of injectables, expanding high potency and specialized manufacturing,

Alira Health Achieves AWS Select Consulting Partner Status1.12.2020 17:00:00 EETPress release

Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced it has recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities to provide greater value to clients, providing fully compliant, made-to-measure digital solutions, powered by AWS, that securely enable the use of data generated by the healthcare community and clients’ own internal data. The solutions are provided to customers in the form of Software-as-a-Service (SaaS), seamlessly integrating into existing workflows and designed to support clients in prioritizing research and development (R&D) investments, identifying novel therapeutic areas suitable for corporate business development, and assessing business opportunities. “Technology has the power to solve complex problems and be a transformative tool across the healthcare and life sciences ecosystem,” said

Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners1.12.2020 17:00:00 EETPress release

Market Access Transformation (MAT), a global healthcare company that uses cutting edge technology to automate and modernize how life sciences companies capture mission-critical insights that drive decision-making across the product lifecycle, today announced a $30 million minority investment from Silversmith Capital Partners, a Boston-based growth equity firm. The investment marks the first time MAT has raised outside capital and will be used to expand the company’s team and accelerate innovation of its product offerings. Founded in 2016, MAT has revolutionized the way Global Payer Market Research is conducted by developing Rapid Payer Response (RPR), the industry’s only on-demand global platform for gathering critical payer insights. In five years, the company has built a client base of more than 45 biopharma and device manufacturers – including all of the Top 10 pharma companies. MAT’s partnership with Silversmith solidifies its market leadership position in providing technology-driv

Rimini Street Awarded Three Brazilian Public Sector Contracts to Support Oracle and SAP Enterprise Software Systems1.12.2020 17:00:00 EETPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has been awarded three separate contracts to provide enterprise software support to agencies linked to the Legislative, Executive and Judiciary branches of the Brazilian government, specifically the Chamber of Deputies, the Superior Labor Court and APEX Brasil, an independent social service agency. The Brazilian government public procurement processes were put in place to ensure that public sector organizations work with providers in a manner that is transparent, efficient, ensures economy of scales and the best optimization of public resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005501/en/ Rimini Street Awarded Three Brazilian Public Sector Contracts to Support Oracle and SAP Enterp

Velodyne Lidar Announces Autonomous Driving Collaboration with Ford Otosan1.12.2020 16:00:00 EETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR) today announced it is collaborating with Ford Otosan on product development and testing of autonomous heavy commercial trucks. Ford Otosan is testing and planning to use Velodyne Velarray H800 lidar sensors to enable safe navigation and collision avoidance in next generation vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005505/en/ Ford Otosan is testing and planning to use Velodyne Velarray H800 lidar sensors to enable safe navigation and collision avoidance in next generation vehicles. (Photo: Ford Otosan) Velarray H800 is a powerful solution that can greatly improve automated safety and advanced driver assistance systems (ADAS). Designed for automotive-grade performance and durability, the Velarray H800’s compact, embeddable form factor makes it ideal for seamless integration in internal and external vehicle mounting locations. The Velarray H800 boasts outstanding range,

Thales Introduces Ready to Fly – a Portfolio of Solutions for a Safer & Healthier Travel Journey1.12.2020 16:00:00 EETPress release

The Ready to Fly portfolio of solutions offered by Thales are designed to help our airline customers restore passenger confidence in air travel during the crisis and in a post pandemic world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005443/en/ Ready to Fly solution ©Thales With Ready to Fly, Thales InFlyt Experience is focused on expediting the industry’s digital transformation through passenger-centric solutions and integrated products as well as services that increase crew efficiency. Ready to Fly solutions enable cabin innovations that reduce touch and mitigate passenger congestion. The Ready to Fly “touchless” solutions allow passengers to safely control the inflight entertainment system with their personal phone or tablet for a full IFE experience, including digital versions of onboard paper menus, magazines and important safety and health information. To reduce physical interactions with the crew, while max

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom